Podcasts about Molecular imaging

In this series, we are exploring the common and not-so-common specialties in medicine. Nuclear medicine sits at the crossroads of imaging and molecular science, revealing how disease behaves at a cellular level rather than just how it looks. In this episode, we explore how this often-overlooked specialty is shaping diagnosis, guiding therapy, and redefining the future of precision medicine.Dr. Erica Major is the Assistant Chief of Nuclear Medicine and Site Director of Radiology and Nuclear Medicine Education at Edward Hines VA, where she oversees medical student and resident training. She holds multiple leadership positions in the American College of Nuclear Medicine and the Society of Nuclear Medicine and Molecular Imaging, and is a past member of the ACGME Residency Review Committee. Her primary interest is advancing the field of theranostics, which combines nuclear oncology with personalized cancer therapy. You can contact Dr. Major at erica.major@va.gov To learn more about nuclear medicine, check out these sources:https://acnmonline.org/https://snmmi.org/ Episode produced by: Rasa ValiaugaEpisode recording date: 4/2/26www.medicuspodcast.com | medicuspodcast@gmail.com | Donate: http://bit.ly/MedicusDonate

Dr. Babak Saboury, Chief Scientific and Innovation Officer and Physician Founder of United Theranostics, discusses the emergence of nuclear oncology as the fourth pillar of cancer care.  United Theranostics is combining advanced molecular imaging and radiopharmaceutical therapies to identify a cancer cell's unique fingerprint and then delivering targeted radiation, reducing side effects by sparing healthy cells. Molecular imaging can serve as a unifying map for guiding a collaborative, multimodal approach to treating a range of cancers.  Babak explains, "I can just very quickly tell you that there are four pillars of treating cancer. Traditionally, when we approached cancer, we wanted to cut it out. That was surgical oncology. Whatever could not be cut out was treated by giving a medication. That was medical oncology. After a while, there was just a modality to the things that were difficult to cut out, but that was a localized hit from outside. That was the radiation oncology. And right now, we are at the beginning of a new horizon. You treat patients systemically, which means all the lesions everywhere. However, you are really there, a magical radiopharmaceutical that goes to find the cell and kills it by radiation. That's a nuclear oncology. So nuclear oncology is the fourth pillar of cancer care."   "So you can imagine that in the past we tried to attack cancer cells. We didn't know what shape they had, which proteins were expressed, or what their characteristics were. So we kind of went blindly and tried to attack them. Imagine that we have a way to find a fingerprint of those cells and go there first to find that fingerprint. And if the fingerprint exists, then go after those cells as a targeted attack. That is where molecular imaging and radiopharmaceutical therapy come into play. So molecular imaging profiles the cancer cells to see what their fingerprint is and whether a certain fingerprint exists. Radiopharmaceutical therapy uses this information to target just those cells and not other cells. And that is the principle of Theranostics, which is a combination of diagnostics and therapeutics, finding and then destroying in a very precise manner." #UnitedTheranostics #NuclearOncology #PrecisionMedicine #Radiopharmaceuticals #CancerCare #MolecularImaging #Theranostics #OncologyInnovation #PatientCare #HealthcareInnovation #CancerTreatment Unitedtheranostics.com Download the transcript here

Dr. Babak Saboury, Chief Scientific and Innovation Officer and Physician Founder of United Theranostics, discusses the emergence of nuclear oncology as the fourth pillar of cancer care.  United Theranostics is combining advanced molecular imaging and radiopharmaceutical therapies to identify a cancer cell's unique fingerprint and then delivering targeted radiation, reducing side effects by sparing healthy cells. Molecular imaging can serve as a unifying map for guiding a collaborative, multimodal approach to treating a range of cancers.  Babak explains, "I can just very quickly tell you that there are four pillars of treating cancer. Traditionally, when we approached cancer, we wanted to cut it out. That was surgical oncology. Whatever could not be cut out was treated by giving a medication. That was medical oncology. After a while, there was just a modality to the things that were difficult to cut out, but that was a localized hit from outside. That was the radiation oncology. And right now, we are at the beginning of a new horizon. You treat patients systemically, which means all the lesions everywhere. However, you are really there, a magical radiopharmaceutical that goes to find the cell and kills it by radiation. That's a nuclear oncology. So nuclear oncology is the fourth pillar of cancer care."   "So you can imagine that in the past we tried to attack cancer cells. We didn't know what shape they had, which proteins were expressed, or what their characteristics were. So we kind of went blindly and tried to attack them. Imagine that we have a way to find a fingerprint of those cells and go there first to find that fingerprint. And if the fingerprint exists, then go after those cells as a targeted attack. That is where molecular imaging and radiopharmaceutical therapy come into play. So molecular imaging profiles the cancer cells to see what their fingerprint is and whether a certain fingerprint exists. Radiopharmaceutical therapy uses this information to target just those cells and not other cells. And that is the principle of Theranostics, which is a combination of diagnostics and therapeutics, finding and then destroying in a very precise manner." #UnitedTheranostics #NuclearOncology #PrecisionMedicine #Radiopharmaceuticals #CancerCare #MolecularImaging #Theranostics #OncologyInnovation #PatientCare #HealthcareInnovation #CancerTreatment Unitedtheranostics.com Listen to the podcast here

In today's episode, we had the pleasure of speaking with Daniel Spratt, MD, chair and professor in the Department of Radiation Oncology at Case Western Reserve University School of Medicine and a member of the Case Comprehensive Cancer Center in Cleveland, Ohio. Dr Spratt discussed key updates to the National Comprehensive Cancer Network (NCCN) Guidelines for prostate cancer, including how advances in molecular imaging, evolving systemic therapy options, and the integration of next-generation androgen deprivation therapy (ADT) are reshaping treatment recommendations across localized, recurrent, and advanced disease settings.

Algernon Health CEO Christopher Moreau joined Steve Darling from Proactive to announce that the company has entered into a significant strategic business and investment agreement with American Molecular Imaging, one of the premier radiology reading services providers in the United States. The partnership is designed to ensure that every patient visiting Algernon's planned U.S. brain-focused neuroimaging clinics receives top-tier PET scan interpretations delivered with unmatched accuracy and turnaround times. Moreau explained that Algernon's planned clinic network will introduce the first dedicated, brain-optimized PET neuroimaging centers in the United States, facilities engineered to detect early signs of Alzheimer's disease with exceptional precision. In addition to Alzheimer's diagnostics, the clinics will offer advanced PET imaging for a broad range of neurological conditions, including other dementias, epilepsy, neuro-oncology indications, and movement disorders. Under the terms of the new partnership, AMI will become the exclusive radiology reading services provider for all of Algernon's future neuroimaging clinics. To further strengthen the collaboration, AMI will make a US$250,000 strategic investment in Algernon's recently announced private placement, and an additional US$250,000 investment into Algernon USA LLC—the company's newly formed subsidiary tasked with overseeing all U.S. neuroimaging operations. Algernon USA LLC is leading efforts to open the first clinic, currently targeted for early 2026. Moreau also highlighted another key milestone: Algernon has finalized an equipment order, financing package, and consulting agreement with Catalyst MedTech, a recognized leader in medical imaging technologies. This non-dilutive arrangement, valued at over CAD $4 million, includes four FDA-cleared Oncovision CareMiBrain™ PET scanner systems that will equip the first wave of Algernon's U.S. clinics. The deal also provides for the acquisition of six additional systems at a reduced cost as the company expands its footprint across the country. #proactiveinvestors #algernonpharmaceuticalsinc #cse #agn #otcqb #agnpf #alzheimerdisease #demetia #AlgernonHealth #AlzheimersDiagnosis #PETScan #BrainImaging #MedicalTechnology #HealthcareInvestment #NeuroImaging #StrategicPartnership #RadiologyInnovation

About a year ago we released an episode on the future of ultrafast electronics and it quickly became one of our most popular episodes on YouTube. We're excited to re-share it with you today. Physicist Matthias Kling walks us through his study of photons and the things science can do with ultrafast pulses of x-rays. The knowledge he's gaining could reshape fields like materials science, artificial intelligence, ultrafast and quantum computers, and medical diagnostics. We hope you'll tune in again wherever you get your podcasts. And as a reminder, we post full video versions of each of our episodes on YouTube every Friday, so be sure to check those out if you haven't already.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Matthias KlingConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Matthias Kling, a professor of photon science and applied physics at Stanford University.(00:02:21) Ultrafast ElectronicsNew technologies enabling ultrafast photonics and electronics.(00:05:40) Attosecond Science ApplicationsCapturing electron and molecular movements with attosecond pulses.(00:10:23) Real-Time Molecular MeasurementsHow free-electron lasers enable detailed, atom-specific measurements.(00:15:02) Free-Electron LasersUsing light waves to capture images of molecules at room temperature.(00:22:28) Electronics at Light SpeedWhether attosecond science could enable computing at petahertz speed.(00:26:24) Lightwaves & Quantum ComputingHow lightwave electronics could allow for energy-efficient quantum computers.(00:29:29) AI Meets Ultrafast ScienceAI's role in optimizing research and data collection in ultrafast electronics.(00:31:47) The Future of Ultafast ElectronicsHow attosecond science, computing, and AI converge to accelerate innovation.(00:35:25) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This podcast is brought to you by Lilly, member of the SNMMI Value Initiative Industry Alliance. Hosts Anupa Arora, MD and Anthony “Nino” Sireci, MD discuss a New Era in Alzheimer Diagnostics. This episode takes a focused look at high-impact topics shaping the future of Nuclear Medicine and Molecular Imaging, designed specifically for professionals driving value in the field. 

Can AI help radiologists see what humans can't—and speed up drug development in the process?In this episode of SNiPs, Dr. Ben Larimer joins Bracken CEO Dr. Colin Miller to explore how artificial intelligence and machine learning are redefining what's possible in molecular imaging. From interpreting complex PET scans to designing radiopharmaceuticals faster than ever, the future of diagnostics is being shaped by intelligent tools.Dr. Larimer shares real-world examples of how AI is already shaping radiopharmaceutical innovation and clinical trial design—and why the era of data-driven diagnostics is just getting started.Topics include:PET imaging and tumor heterogeneityAI-assisted radiologyAccelerating development of imaging agentsThe promise of radiomics and multimodal dataTune in now and explore how intelligent tools are reshaping life sciences from pixel to patient.

AUA2025: Should I Order a PET Scan? Integrating Molecular Imaging Into Urologic Oncology Clinical Practice: Current Approaches and Future Opportunities CME Available: https://auau.auanet.org/node/43003 At the conclusion of this activity, participants will be able to: 1. Analyze the best available evidence on the current diagnostic imaging options for prostate, kidney, bladder, and testis cancer detection, staging, and follow-up. 2. Identify the benefits of combined functional and anatomic information gained through accurate matching of anatomic (CT/MRI) and functional (PET) images 3. Debate the strengths and limitations of emerging molecular imaging techniques compared to existing diagnostic tests. 4. Optimally stage urologic oncology patients by understanding the performance characteristics of standard and emerging molecular imaging modalities. 5. Identify the emerging role of PET imaging and novel radiotracers to assess chemotherapy and immunotherapy response. 6. Formulate a strategic plan for appropriate integration of molecular imaging into clinical practice. ACKNOWLEDGEMENTS: This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.

Biomarkers and Molecular Imaging for Prostate Cancer CME Available: auau.auanet.org/node/41727 ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Lantheus Medical Imaging Novartis Pharmaceuticals Corporation LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Explain the principles of molecular imaging and its application in prostate cancer, including techniques such as PET, MRI, and novel radiotracers. 2. Evaluate recent advances in molecular imaging technologies and their role in improving the accuracy of prostate cancer diagnosis, staging, and treatment monitoring. 3. Define and classify different types of biomarkers relevant to prostate cancer, including diagnostic, prognostic, and predictive biomarkers.

Life Healthcare R14bn sale of Life Molecular Imaging is the focus of this edition of Business Day Spotlight. Host Mudiwa Gavaza is joined by Peter Wharton-Hood, CEO of Life Healthcare Group. Topics of discussion include: Peter Wharton-Hood outlines the rationale for the transaction; relationship with Lantheus; capital allocation; and investment in technology. Business Day Spotlight is a MultimediaLIVE Production

Stephen Grootes speaks to Life Healthcare CEO Peter Wharton-Hood about the company's $750 million sale of Life Molecular Imaging to Lantheus Neurology UK Limited.See omnystudio.com/listener for privacy information.

Nosipho Radebe speaks to Peter Wharthon-Hood, CEO at Life HealthcareSee omnystudio.com/listener for privacy information.

Terry Pearl is a proven leader and successful strategist in development, strategic planning, fundraising campaigns, major gifts, corporate and foundation relations, and board development. Over a philanthropic career spanning two decades, she has cumulatively raised more than $175 million for nonprofits across the globe, including principal gifts as large as $50 million. As a development consultant, she has worked with a diverse group of organizations including the Society of Nuclear Medicine and Molecular Imaging, American Society for the University of Haifa, Hadassah of America, HousingPlus, the Green Beret Foundation, the Network of Jewish Human Service Agencies, T1D Exchange, the YWCA of New York City, Overlook Medical Center, and several Hackensack Meridian Health hospitals. 

GUEST: John Ronald, London (ON, Canada)Welcome back!  It has been a while but are back with a bang, having our good friend John Ronald from The Robarts Research Institute in London, Ontario as our guest. John's group combines advances in molecular and synthetic biology with a multimodal imaging perspective to build new tools for early detection and treatment of cancer, as well as non-invasive monitoring of cell, gene and genome therapies. One of John's passions is gene reporter imaging, which is also the main focus of this edition. The paper up for discussion comes from Cynthia Dunbar's lab at NIH, Bethesda which was recently published in Cell Stem Cell. We discover their approach to non-invasively follow engraftment and maturation of pluripotent stem cells in rhesus macaques with myocardial infarctions, discuss some of the technicalities of engineering autologous cells, and fall in love with the beautiful RNAScope images that are presented. We discuss what makes a good imaging reporter, why one size doesn't always fit all, and a future where not just cells, but activation states can be imaged. Along the way, John also shares advices received from the wonderful Sanjiv Sam Gambhir on how to improve the chances of getting your grants funded and that supposedly crazy ideas should not be discarded... they might even lead to high impact publications.And of course, true to our tradition, we enjoy a special cocktail. For this edition the “Angry Canadian”, obviously. For the curious listeners: a good measure of Whisky, 2 tablespoons of fine Canadian Maple syrup, a few drops of bitters and 1 teaspoon lemon juice, then top up with soda water.Selected Publication: Lin Y, Sato N, Hong S, Nakamura K, Ferrante EA, Yu ZX, Chen MY, Nakamura DS, Yang X, Clevenger RR, Hunt TJ, Taylor JL, Jeffries KR, Keeran KJ, Neidig LE, Mehta A, Schwartzbeck R, Yu SJ, Kelly C, Navarengom K, Takeda K, Adler SS, Choyke PL, Zou J, Murry CE, Boehm M, Dunbar CE. Long-term engraftment and maturation of autologous iPSC-derived cardiomyocytes in two rhesus macaques. Cell Stem Cell. 2024 Jul 5;31(7):974-988.e5. doi: 10.1016/j.stem.2024.05.005. Epub 2024 Jun 5. PMID: 38843830; PMCID: PMC11227404. https://www.cell.com/cell-stem-cell/abstract/S1934-5909(24)00182-6Further information on the European Society for Molecular Imaging:https://e-smi.eu/Contact: office@e-smi.eu 

May Abdel-Wahab (Division of Human Health, Department of Nuclear Science and Applications, International Atomic Energy Agency, Vienna, Austria) and Andrew Scott (Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia) discuss The Lancet Oncology Commission on Radiotherapy and Theranostics.Read the Commission:https://www.thelancet.com/commissions/radiotherapy-theranostics?dgcid=buzzsprout_icw_podcast_generic_lanoncTell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Join us for an inspiring discussion with Dr. Akiva Mintz, a physician-scientist whose translational research focuses on developing and personalizing cancer therapies using non-invasive molecular imaging. Learn about the role of nuclear medicine in molecular based cancer therapies and the life of a physician scientist.

This podcast is brought to you by United Imaging, co-chair of the SNMMI Value Initiative Industry Alliance. Hosts Dr. Munir Ghesani, former President of SNMMI, co-Chair of the Mars Shot Research Fund, and Dr. Stephen Lokitz, a NM physician at the Center for Molecular Imaging and Therapy, or CMIT, discuss nuclear medicine procedures performed and their plans for the future."

Biomarkers and Molecular Imaging for Prostate Cancer CME Available: https://auau.auanet.org/node/41727 ACKNOWLEDGEMENTS: Support provided by independent educational grants from:  Lantheus Medical Imaging Novartis Pharmaceuticals Corporation LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Explain the principles of molecular imaging and its application in prostate cancer, including techniques such as PET, MRI, and novel radiotracers. 2. Evaluate recent advances in molecular imaging technologies and their role in improving the accuracy of prostate cancer diagnosis, staging, and treatment monitoring. 3. Define and classify different types of biomarkers relevant to prostate cancer, including diagnostic, prognostic, and predictive biomarkers.

In today's episode, we delve into the world of PET scans and other imaging modalities crucial for accurate diagnosis and staging of breast cancer. We are joined by two incredible guests: Dr. Kiser, the Medical Director of Molecular Imaging for Carilion Clinic, and Pam Kohl, a patient advocate living with metastatic breast cancer.Dr. Kiser provides an in-depth explanation of PET scans, particularly focusing on FDG and FES (also known as Cerianna) PET scans. FDG-PET scans use radioactive glucose to highlight cancerous tissues, while FES-PET scans target estrogen receptors, making them highly specific for ER-positive breast cancer. Dr. Kiser emphasizes the revolutionary impact of these imaging techniques in both diagnostics and therapeutics.Pam shares her personal experience with breast cancer, highlighting the importance of advocating for oneself. Diagnosed with early-stage breast cancer in 2009, Pam experienced a recurrence in 2017, which led to a stage 4 metastatic diagnosis. Her story underscores the critical role of PET scans in detecting metastasis early and informing effective treatment plans. Pam's experience with FES-PET scans has been particularly transformative, allowing her medical team to tailor her treatment precisely to her cancer's characteristics.SURVIVINGBREASTCANCER.ORGAttend a free virtual SurvivingBreastCancer.org event:https://www.survivingbreastcancer.org/eventsFollow us on InstagramSurvivingBreastCancer.org: https://www.survivingbreastcancer.org/Breast Cancer Conversations: https://www.instagram.com/breastcancerconversations/About SurvivingBreastCancer.org: SurvivingBreastCancer.org, Inc. (SBC) is a federally recognized 501(c)(3) non-profit virtual platform headquartered in Boston with a national and global reach. Through education, community, and resources, SurvivingBreastCancer.org supports women and men going through breast cancer. We provide a sanctuary of strength, compassion, and empowerment, where those diagnosed with cancer unite to share their stories, learn invaluable coping strategies to manage wellness and mental health, and find solace in the unbreakable bond that fuels hope, resilience, and the courage to conquer adversity.Support the Show.

Identifying reliable biomarkers for the diagnosis and prognosis of Parkinson's disease and atypical parkinsonism would have substantial impacts on clinical trials and clinical practice. A particularly active area of research is the development of novel molecular imaging biomarkers that can be used in combination with common neuroimaging approaches. Dr. Antonio Strafella discusses current practices for using molecular imaging biomarkers in research and in the clinic, the process of developing new biomarkers, as well as promising biomarkers that are in development. He also discusses limitations, implementation challenges, and the potential use of AI to enhance diagnostics in the future. Antonio is the Krembil-Rossy Chair in Molecular Imaging of Neurodegenerative Diseases and Professor in the Department of Medicine within the Division of Neurology at the Toronto Western Hospital (University Health Network, University of Toronto). He also serves as Director of Clinical Research and Translation with the Temerty Faculty of Medicine at the University Toronto, and he is a movement disorder neurologist in the Edmond J. Safra Program in Parkinson's Disease and Morton & Gloria Shulman Movement Disorders Clinic at the Toronto Western Hospital.This podcast is geared toward researchers and clinicians. If you live with Parkinson's or have a friend or family member with PD, listen to The Michael J. Fox Foundation Parkinson's Podcast. Hear from scientists, doctors and people with Parkinson's on different aspects of life with the disease as well as research toward treatment breakthroughs at https://www.michaeljfox.org/podcasts.

Identifying reliable biomarkers for the diagnosis and prognosis of Parkinson's disease and atypical parkinsonism would have substantial impacts on clinical trials and clinical practice. A particularly active area of research is the development of novel molecular imaging biomarkers that can be used in combination with common neuroimaging approaches. Dr. Antonio Strafella discusses current practices for using molecular imaging biomarkers in research and in the clinic, the process of developing new biomarkers, as well as promising biomarkers that are in development. He also discusses limitations, implementation challenges, and the potential use of AI to enhance diagnostics in the future. Antonio is the Krembil-Rossy Chair in Molecular Imaging of Neurodegenerative Diseases and Professor in the Department of Medicine within the Division of Neurology at the Toronto Western Hospital (University Health Network, University of Toronto). He also serves as Director of Clinical Research and Translation with the Temerty Faculty of Medicine at the University Toronto, and he is a movement disorder neurologist in the Edmond J. Safra Program in Parkinson's Disease and Morton & Gloria Shulman Movement Disorders Clinic at the Toronto Western Hospital.This podcast is geared toward researchers and clinicians. If you live with Parkinson's or have a friend or family member with PD, listen to The Michael J. Fox Foundation Parkinson's Podcast. Hear from scientists, doctors and people with Parkinson's on different aspects of life with the disease as well as research toward treatment breakthroughs at https://www.michaeljfox.org/podcasts.

Host: Jennifer Caudle, DO Guest: Geoffrey B. Johnson, M.D., Ph.D. Prostate-specific membrane antigen (PSMA) PET scans are a method by which clinicians can see if a patient who is suffering from prostate cancer has tumors that are expressing the PSMA target. In addition to that, the scan allows us to measure how much of the medication we get onto that cancer target and if it's going to be effective. Take a deep dive with Dr. Jennifer Caudle as she speaks with Dr. Geoffrey Johnson, Nuclear Medicine Specialist and Radiologist at the Mayo Clinic in Rochester, Minnesota, who also presented this research at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting.

Host: Jennifer Caudle, DO Guest: Geoffrey B. Johnson, M.D., Ph.D. Prostate-specific membrane antigen (PSMA) PET scans are a method by which clinicians can see if a patient who is suffering from prostate cancer has tumors that are expressing the PSMA target. In addition to that, the scan allows us to measure how much of the medication we get onto that cancer target and if it's going to be effective. Take a deep dive with Dr. Jennifer Caudle as she speaks with Dr. Geoffrey Johnson, Nuclear Medicine Specialist and Radiologist at the Mayo Clinic in Rochester, Minnesota, who also presented this research at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting.

Guest: Joyita Dutta The AI landscape is evolving at a rapid pace. However, there is a shortage of large public data sets in nuclear medicine that AI models can be trained on. To learn more about what's on the AI horizon and the challenges that are associated, join Dr. Joyita Dutta, Associate Professor at the University of Massachusetts, Amherst in the Department of Biomedical Engineering, who also presented this at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting.

Guest: Joyita Dutta The AI landscape is evolving at a rapid pace. However, there is a shortage of large public data sets in nuclear medicine that AI models can be trained on. To learn more about what's on the AI horizon and the challenges that are associated, join Dr. Joyita Dutta, Associate Professor at the University of Massachusetts, Amherst in the Department of Biomedical Engineering, who also presented this at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting.

Molecular imaging tests can offer comprehensive views of breast cancers, especially for locally advanced or metastatic breast cancer, and can help paint a clearer picture of the extent and characteristics of the cancer. This can then give doctors the ability to help guide treatment and evaluate response to treatment. Joining us on today's show is Dr. David Mankoff, Vice Chair of Research, Radiology and the Matthew J. Wilson Professor of Radiology at the University of Pennsylvania and Associate Director of Education and Training at Penn's Abramson Cancer Center. Dr. Mankoff is going to help us understand the complexities of breast cancer tumors, what these molecular imaging tests are looking for and who should be getting them.

What is PRRT? How is it different from the more commonly used radiation treatment? What are the possible side effects? Dr. Riham El Khouli from the University of Kentucky in Lexington discusses common questions and concerns about PRRT and shares some of the latest advances.MEET DR. RIHAM EL KHOULI, MD, PHDAssociate Professor of Radiology, UK College of MedicineChief, Division of Nuclear Medicine/Molecular Imaging & Radiotheranostics (NM/MI&R)Director, Radiotheranostics ProgramUniversity of KentuckyDr. Riham El Khouli, MD PhD, is the director of the Radiotheranostics program and Chief of the division of NM/MI&R at the University of Kentucky and an Associate Professor of Radiology, Nuclear Medicine and Molecular Imaging at UK school of Medicine.TOP TEN QUESTIONS ABOUT NET TREATMENTS:1. What is PRRT?  How does it work? 2. What is theranostics and what does it mean? What are the terms radiotheranostics, radiopharmaceutical, radioligand therapy, PRRT?3. How do you determine who is eligible for PRRT?4. When is PRRT given in one's treatment journey? 5. How does PRRT differ from other treatments?6. What are the common side effects of Lutathera?a. Does Lutathera have long-lasting effects?b. Would receiving Lutathera affect one's blood counts?c. How might Lutathera affect one's liver function? When, if ever is there concern about liver failure?7. How might PRRT affect my quality of life and my day-to-day ability to work and function? What is the risk and effects of radiation with receiving Lutathera? a. What precautions do I need to follow?b. Can I hug my child? Can I pet my dog? c. Would receiving Lutathera cause someone to be immunocompromised? 8. How to you decide who should get PRRT?a. What is peritoneal disease and how effective is PRRT with peritoneal disease?9. How do you assess the response to PRRT? 10. What advances in PRRT are you most excited about? Visit https://www.lacnets.org/podcast/34. For more information, visit LACNETS.org.

Radiopharmaceuticals are precision nuclear medicines used for medical imaging and treatment that allow doctors to diagnose and deliver targeted therapies for diseases such as cancer. A new discussion paper from MTPConnect, ‘From Mines to Medicines. Australia's Radiopharmaceuticals Future' reveals how Australia is ready to play a leading role in the rise of the global radiopharmaceutical industry, as advanced therapies drive significant investment and rapid expansion. South Australia is identified as the ideal location to lead the development of Australia's radiopharmaceuticals future, with end-to-end capabilities – from unique mining assets and a robust research ecosystem through to cutting-edge clinical services and specialised workforce. In this feature length episode, hosts Caroline Duell and Dana Bell, MTPConnect's Partnerships Director South Australia, speak to experts in South Australia along the supply chain - from mines to medicines including: UniSAs Professor Eva Bezak, Deputy Director of the Australian Research Council's Industrial Transformation Training Centre (ITTC) for Radiation Innovation (Time code: 10.32) on researching new radiopharmaceuticals and building a highly skilled workforce to scale up,  SAHMRI's Chady Barkil, Director, Molecular Imaging and Therapy Research Unit (MITRU) (Time code: 35.43) on manufacturing nuclear medicines and the supply chain challenges,EntX's Dr Massey de Los Reyes, Principal Scientist and Facilities Manager, on developing technology to transform mining waste into medical isotope production (at Time code: 57.36),Novartis ANZ's Matt Zeller, Country President (Time code: 1.17.03) on how the company is reimagining cancer care with its precision nuclear medicine pipeline,Artesian's Stephanie Morris, Investment Manager (Time code: 1.36.02) discusses the investment activity and interest in the growing radiopharmaceuticals market and,Department for Industry, Innovation and Science's Dr Judy Halliday, Director Innovation and Entrepreneurship (Time code: 1.48.06) outlines South Australia's strengths as a first mover to unlock the radiopharmaceutical industry opportunity. 

In this episode of Talking HealthTech recorded at Healthcare Week in Hamilton New Zealand, host Peter Birch speaks with Jane Prowse, CTO of FiveP, and Nicole Hosking, Operations Director for Radiology and Molecular Imaging and Therapy at Austin Health. They discuss the development of the Baret role-based communicator app, a solution that addresses communication challenges in Austin Health. Jane and Nicole share insights into the creation of the app, its functionality, and the impact it has had on clinical workflows.Key Takeaways:- The Baret app was developed to address complex communication challenges, such as finding the right person to communicate with 24/7 and minimising the use of multiple communication methods.- The app leverages Microsoft Teams for seamless integration, reducing the need for additional logins and authentication steps.- Baret focuses on clinical governance, incorporating measures to ensure communication quality, safety, and risk management within the hospital environment. It also provides valuable data insights for better assessment of communication quality and workload.Check out the episode and full show notes on the Talking HealthTech website.Loving the show? Leave us a review, and share it with someone who might get some value from it.Keen to take your healthtech to the next level? Become a THT+ Member for access to our online community forum, quarterly summits, and more exclusive content. For more information visit talkinghealthtech.com/thtplus

Dr. Linda Chu discusses the future of molecular imaging with Dr. Umar Mahmood, Chair of the RSNA Board of Directors.   Molecular Imaging, Oncology, and the Arc toward Our Precision Future. Mahmood. Radiology 2023; 309(2):e231930.

Some of the rarest, most complex, challenging and difficult NETs are known as pheochromocytomas and paragangliomas. This is an updated version of an episode that first aired in 2021. A special thank you to Dr. Erik Mittra Chief of Nuclear Medicine and Molecular Imaging at Oregon Health and Science University for his expert assistance with […] The post NETWise Episode 32: Pheos & Paras (updated episode) appeared first on NETRF.

GUEST: Kevin Brindle, CambridgeIn this episode we welcome the one and only Kevin Brindle from University of Cambridge.During his long and illustrious career, Kevin pioneered hyperpolarized magnetic resonance spectroscopy as a method to map metabolic flux in cancer and other diseases, with implications for treatment response monitoring.We explore how deuterium imaging and [18F]FDG PET can be used to track the metabolic changes that occur soon after stroke and during the recovery phase. We discuss the complementary information that these two techniques provide and whether they could be used to improve clinical outcomes.Along the way, we learn how Kevin could have worked in structural biology or been a painter and decorator... and how he used to meet his wife-to-be in the cold room when he was a postdoc at Oxford.Selected Publication: In vivo imaging of cerebral glucose metabolism informs on subacute to chronic post-stroke tissue status - A pilot study combining PET and deuterium metabolic imaging. Meerwaldt AE, Straathof M, Oosterveld W, van Heijningen CL, van Leent MM, Toner YC, Munitz J, Teunissen AJ, Daemen CC, van der Toorn A, van Vliet G, van Tilborg GA, De Feyter HM, de Graaf RA, Hol EM, Mulder WJ, Dijkhuizen RM. J Cereb Blood Flow Metab. 2023 May;43(5):778-790. doi: 10.1177/0271678X221148970. Epub 2023 Jan 6.https://journals.sagepub.com/doi/10.1177/0271678X221148970 Further information on the European Society for Molecular Imaging: https://e-smi.eu/ Contact: office@e-smi.eu 

Guest host Dr. Gagandeep Choudhary summarizes the article “Multimodality Imaging of Dementia: Clinical Importance and Role of Integrated Anatomic and Molecular Imaging” focusing on pathophysiology and imaging findings of some of the major neurodegenerative processes.  Multimodality Imaging of Demen-tia: Clinical Importance and Role of Integrated Anatomic and Mo-lecular Imaging. Patel et al. RadioGraphics 2020; 40:200–222.

GUEST: Mikhail Shapiro, PasadenaIn this episode we welcome our famous guest Mikhail Shapiro from Caltech. Mikhail exquisitely combines ultrasound with synthetic biology for gene regulation, imaging, and therapy - and Synthetic biology is surely the common thread in this podcast edition.We discover how an engineered receptor and an intracellular signalling domain, known as ‘synNotch' can be used to visualise cell-cell communication in vivo. And how this system can be used to identify immune-cancer cell interactions, why it provides far more information than just knowing where the immune cells reside, and the various merits of the three different reporter genes employed for visualisation across scales.We also reveal some insider information into the review process for the selected paper from the senior author John Ronald. Along the way, we speculate why the synNotch system improves NK cell kill and Tim ends up dreaming of sheep jumping over logic gates!Selected Publication: Visualizing cell–cell communication using synthetic notch activated MRI. TianDuo Wang, Yuanxin Chen, Nivin N Nystrom, Shirley Liu, Yanghao Fu, Francisco M Martinez, Timothy J Scholl, and John A Ronald. Proc Natl Acad Sci U S A. 2023 Mar 14; 120(11):e2216901120. doi: 10.1073/pnas.2216901120.https://www.pnas.org/doi/abs/10.1073/pnas.2216901120Further information on the European Society for Molecular Imaging:https://e-smi.eu/Contact: office@e-smi.eu

This week we have a very special guest, Hilma Johnson, account executive at DISS Medical Solutions and Molecular Imaging specialist. In this episode we talk about the importance of Molecular Imaging in accurate diagnoses and his experience as a nuclear medicine technologist.

GUEST: Jason Lewis, New YorkIn this episode we discuss and learn about new PSMA-binding ligands with 161Tb, their biodistribution, dosimetry, preclinical therapy, and their comparison with conventional PSMA ligands. Our guest is one of the leading scientists in radiochemistry for cancer detection and therapy, the wonderful Jason Lewis. We talk about the importance of using 161Tb - this novel radionuclide for radioligand therapy - and its favorable decay characteristics as compared to 177Lu. We learn about the added value of the emission of Auger electrons which can effectively eliminate micro-metastasis and when combined with ibuprofen-based PSMA ligands offering albumin-binding properties, tumor uptake and therapeutic efficacy are significantly boosted. Besides this fascinating science, don't miss some very important advice from a very successful scientist in a very competitive environment about work-life balance, prioritising expectations and goals - just never forget to "smell the roses"…Selected Publication: Albumin-Binding and Conventional PSMA Ligands in Combination with 161Tb: Biodistribution, Dosimetry, and Preclinical Therapy. Viviane J. Tschan, Sarah D. Busslinger, Peter Bernhardt, Pascal V. Grundler, Jan Rijn Zeevaart, Ulli Köster, Nicholas P. van der Meulen, Roger Schibli, Cristina Müller. Journal of Nuclear Medicine Jul 2023, jnumed.123.265524; DOI: 10.2967/jnumed.123.265524https://jnm.snmjournals.org/content/early/2023/07/13/jnumed.123.265524Further information on the European Society for Molecular Imaging:https://e-smi.eu/Contact: office@e-smi.eu

       Relebogile speaks to Dr Ntanganedzeni (N) Muambadzi a Specialist in Nuclear Medicine and  Molecular Imaging.See omnystudio.com/listener for privacy information.

GUEST: Annemie Van Der Linden, AntwerpIn this edition of ‘Dive into Imaging Science' we discuss the brain and the mechanisms that it employs to clear unwanted waste material whilst we sleep with our former ESMI President and Emeritus Professor Annemie Van Der Linden - an outstanding figure and incomparable scientist.We learn how closely coupled this system - known as the glymphatics - is to blood circulation, and how physical stimulation can enhance glymphatic flow in anaesthetised but not awake mice. Along the way, we learn how curiosity and a wondering mind has led Annemie to use a wide range of models to study the brain, from fish to song birds.Selected Publication: Glymphatic influx and clearance are accelerated by neurovascular coupling. Holstein-Rønsbo S, Gan Y, Giannetto MJ, Rasmussen MK, Sigurdsson B, Beinlich FRM, Rose L, Untiet V, Hablitz LM, Kelley DH, Nedergaard M. Nat Neurosci. 2023 Jun;26(6):1042-1053. doi: 10.1038/s41593-023-01327-2. Publication reference: Holstein-Rønsbo S, Gan Y, Giannetto MJ, Rasmussen MK, Sigurdsson B, Beinlich FRM, Rose L, Untiet V, Hablitz LM, Kelley DH, Nedergaard M. Glymphatic influx and clearance are accelerated by neurovascular coupling. Nat Neurosci. 2023 Jun;26(6):1042-1053. doi: 10.1038/s41593-023-01327-2. Epub 2023 Jun 1. PMID: 37264158. https://www.nature.com/articles/s41593-023-01327-2Further information on the European Society for Molecular Imaging:https://e-smi.eu/Contact: office@e-smi.eu

Drs Stanley Cohen and Philip Mease review the 2022 ACR meeting topics, including new treatments, trial data, and what they think are the most pressing unmet needs in the field. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984271). The topics and discussions are planned, produced, and reviewed independently of the advertisers. This podcast is intended only for US healthcare professionals. Resources Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis: A Randomised Trial https://pubmed.ncbi.nlm.nih.gov/10972371/ Group for Research and Assessment of Psoriasis and Psoriatic Arthritis https://www.grappanetwork.org/ American College of Rheumatology (ACR) Convergence https://www.rheumatology.org/Annual-Meeting Bimekizumab Treatment in Biologic DMARD-Naïve Patients With Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results From a Phase 3, Randomized, Placebo-Controlled, Active Reference Study https://acrabstracts.org/abstract/bimekizumab-treatment-in-biologic-dmard-naive-patients-with-active-psoriatic-arthritis-52-week-efficacy-and-safety-results-from-a-phase-3-randomized-placebo-controlled-active-reference-study/ Bimekizumab Treatment in Patients With Active Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors: 16-Week Efficacy and Safety From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study https://acrabstracts.org/abstract/bimekizumab-treatment-in-patients-with-active-psoriatic-arthritis-and-inadequate-response-to-tumor-necrosis-factor-inhibitors-16-week-efficacy-and-safety-from-a-phase-3-randomized-double-blind-pla/ Bimekizumab Improvements in Efficacy on Disease Activity Assessed via Composite Endpoints in Biologic DMARD-Naïve and TNFi-IR Patients With Active PsA: Pooled 16-Week Results From Phase 3 Randomized, Placebo-Controlled Studies https://acrabstracts.org/abstract/bimekizumab-improvements-in-efficacy-on-disease-activity-assessed-via-composite-endpoints-in-biologic-dmard-naive-and-tnfi-ir-patients-with-active-psa-pooled-16-week-results-from-phase-3-randomized/ Bimekizumab Versus Adalimumab in Plaque Psoriasis https://pubmed.ncbi.nlm.nih.gov/33891379/ A Head-to-Head Comparison of the Efficacy and Safety of Ixekizumab and Adalimumab in Biological-Naïve Patients With Active Psoriatic Arthritis: 24-Week Results of a Randomised, Open-Label, Blinded-Assessor Trial https://pubmed.ncbi.nlm.nih.gov/31563894/ GRAPPA Treatment Recommendations: 2021 Update https://pubmed.ncbi.nlm.nih.gov/35293339/ Deucravacitinib Prescribing Information https://packageinserts.bms.com/pi/pi_sotyktu.pdf Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients With Psoriatic Arthritis: 52-Week Results From a Randomized Phase 2 Trial https://acrabstracts.org/abstract/safety-and-efficacy-of-deucravacitinib-an-oral-selective-tyrosine-kinase-2-inhibitor-in-patients-with-psoriatic-arthritis-52-week-results-from-a-randomized-phase-2-trial/ Deucravacitinib Reduces Interferons, B Cell Pathways, and Serological Biomarkers of Systemic Lupus Disease Activity: Pharmacodynamic Analysis From the Phase 2 PAISLEY Study https://acrabstracts.org/abstract/deucravacitinib-reduces-interferons-b-cell-pathways-and-serological-biomarkers-of-systemic-lupus-disease-activity-pharmacodynamic-analysis-from-the-phase-2-paisley-study/ Nanobody: A Promising Toolkit for Molecular Imaging and Disease Therapy https://pubmed.ncbi.nlm.nih.gov/33464410/

Dr. Gayatri Gowrishankar, a cancer researcher, talks about how her professional life collided with her personal life when her daughter was diagnosed with a brain tumor. After a number of confusing symptoms, Gayatri followed her motherly instinct when she felt something wasn't right with her daughter's health. Dr. Gowrishankar talks about what her daughter remembers about her experience at the age of 9,  the power of positivity for kids with cancer, and reaching out for support as a caregiver. She also talks about ways to better the experience for childhood cancer patients in India. 1. The power of imaging for cancer early detection 2. How a personal cancer diagnosis motivates and inspires professional work in the cancer research lab 3. Following motherly instinct to push for a diagnosis for your child 4. Caring for yourself when you're a cancer patient's caregiver About the guest: Dr. Gayatri Gowrishankar is a research scientist deeply invested in the business of diagnosing diseases. After being awarded a PhD in Biochemistry from the University of Hannover, Germany, she moved to California to continue her postdoctoral studies in the Molecular Imaging Program at Stanford University where she was introduced to the power of using molecular information to diagnose complex diseases like cancer. She stayed on at Stanford University as a Research Scientist under the mentorship of the late Professor Sanjiv Sam Gambhir who was a pioneer in the field of Molecular Imaging and laid the foundations for early detection programs in Oncology. At Stanford, her work focused around developing novel diagnostic imaging agents, particularly positron emission tomography (PET) tracers for Oncology and Infectious Diseases. She has co-authored numerous scientific publications and participated in several scientific conferences. She is now working in the External Partnerships/Scientific affairs division of Visby Medical, a growing start-up in Silicon Valley with a mission of bringing diagnostics to the patients. Key Moments: 6 minutes: On the science behind and impact of PET scan imaging - Cancer cells are continuing to grow, proliferate and divide, so they need energy and consume a lot of glucose. So that's why they take up this glucose tracer. Then the patients go through the PET scanner and the area where the glucose has been taken up just lights up. And it turns out, it's an exquisitely sensitive modality, or imaging technique, because it's able to pinpoint very small masses of cells all over your body. It tells you where all the cancer has spread in a patient. 22 minutes: On the uncertainty before test results - I think all the mother's listening in will identify because you know when there is something really wrong. You know when there's a simple thing like a scrape and they just need a bandaid. But you know when something's not right with your child. 41 minutes: On reaching out for emotional support as a caregiver -  So I made use of that because I felt like I needed to talk to someone. And it was hard to talk to my husband because we were both so emotional, and we would just break down talking to each other. So I had to reach out for help. Visit the Manta Cares website Disclaimer: This podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user's own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard, or delay in obtaining, medical advice for any medical condition they may have, and should seek the assistance of their health care professionals for any such conditions. --- Support this podcast: https://podcasters.spotify.com/pod/show/manta-cares/support

Alzheimer, Parkinson and EpilepsyThese are degenerating neurons! Neurodegeneration! Our Biomedical Imaging in Neurodegeneration, Book in progress. Join us! By the way- Are you forgetting? Hybrid Imaging Techs, molecular-MRI and neuromolecular- Neuromolecular Imaging.-NMi.Let's put them together. The new kid on the block is working on the next generation sensor- a manufacturer, philanthropist and investor are needed to come together. A licensee is welcome. Let's talk.on the show- 866 451 1451. All techs can see it all!!!!! Then, why is the new kid's tech needed? Each one does something different. Economy, size, no tracers, no tunnels, small encasement and small scanning device- a big word, potentiostat but the device is handheld it is so small and so on.Straight from the team business plan- the benefits- view here.. .Nanobiosensors with NMI: Advanced Sensing Nanotechnology Over Prior Art · Live imaging· Continuous imaging· Inexpensive imaging· No restraint required· Real-time monitoring· In-vivo, in-situ or in-vitro· Generates specific neurochemical "signatures" or waveforms· Reliable signalling for months· Specific brain locations· Molecular Imaging of targeted neurochemicals · Simultaneous brain signalling as movement is monitored· Cause and effect are closely related· Control and disease signalling leads to personalized medicine· Point of Care Medicine· No bacterial infection· No gliosis, scar tissue formed.· Signals not blocked by scar tissue· Direct imaging independent of flow rate· Superior temporal and spatial resolution· Superior operational stability and steady state control· Same subject comparison data· Superior design· Compatible materials· Compact miniature nanobiosensor· Compact miniature amplifier· Low resistance· High conductance· Faster electron transfer· No interference from white noise· Less equipment· Modern portable equipment· Imaging under anesthesia· Imaging while subject is moving· Imaging while subject is behaving in natural state· Imaging while subject is behaving in diseases of movement· Works with Micro Machines(MEMS) Who is Dr. Broderick? Answer: View CV on the screen. What will she do with the funds? Answer: Hire the people she needs to manufacture and market.What company will do it? Answer- Eazysense and Eazysense can merge! Eazysense holds 200 shares.Where will she and her team do it? Her lab, the manufacturer's lab also because more than one lab is necessary. Roald Dahl: Listen with glistening eyes, the world around you as the secret is hidden in the most unusual places. See the magic, the magical, the miracle of the brain! The discoverable is discovered. Dr. Broderick wishes to pass on the joy of discovery!Meet with the youthful, electrochemist, neuroscientist and pharmacologist, see how Albert Einstein College of Medicine, St..John's University, St. Thomas Aquinas College, Cornell University, Bronx Community College. Cathedral HS, and Msgr. Scanlan HS played a role in her life. See how a life of unassuming dedication molded her brain to discover. A life of solitude in prayer mixed with the joy of family, colleagues, friends.Mental bandwidth-let's connect off the show!CUNY Med School -212 650 5479and broderick@med.cuny.eduThe Broderick Brain FoundationPO Box 596, Bx NY, 10465-1111Good night, Good morning, and Good afternoon, all over the world. ...and that's a wrap.

In this edition of Prostate Cancer Uncensored, hear from Mr. Faulk, a prostate cancer survivor, in a discussion with Dr. Joseph Osborne, the Chief of Molecular Imaging and Therapeutics, Professor of Radiology at Weill Cornell Medicine and Attending Radiologist at New York-Presbyterian/Weill Cornell Medicine. To learn more or to listen to additional episodes of Prostate Cancer Uncensored, visit zerocancer.org.

This episode features Simon Cherry, PhD, discussing his recent 2022 Annual Meeting Cassen Award Lecture and more in a wide-ranging conversation with SNMMI President, Munir Ghesani, MD.In his lecture—A Matter of Time—at the SNMMI 2022 Annual Meeting, Cassen Award Winner Simon Cherry, PhD , explored time, and its role in nuclear medicine, from historical developments occurring over decades, to technologies that can detect photons with a precision of tens of picoseconds. Inspired by the groundbreaking ideas of Benedict Cassen and others, Dr. Cherry charted the journey from the past and into the future to create the ultimate imaging devices for studying the body and its many interacting systemsThe Benedict Cassen Prize is awarded by the Education and Research Foundation (ERF) for Nuclear Medicine and Molecular Imaging in recognition of outstanding achievement and work leading to a major advance in nuclear medicine science.

Heather Jacene, MD, SNMMI Scientific Program Chair, sits for a conversation with E.G. Elisabeth de Vries, MD, PhD—the SNMMI 2022 Annual Meeting Henry N. Wagner, Jr., MD, Lectureship Speaker—for a preview of her lecture: Seeing the Light with Molecular Imaging for Systemic Cancer Treatment Decisions. 

Should I Order a PET Scan? Integrating Molecular Imaging Into Urologic Oncology Clinical Practice: Current Approaches and Future Opportunities CME Available: https://auau.auanet.org/node/36003 LEARNING OBJECTIVES At the conclusion of this course, participants will be able to: 1. Analyze the best available evidence on the current diagnostic imaging options for prostate, kidney and urothelial cancer detection, staging and follow-up. 2. Determine the benefits of combined functional and anatomical information gained through accurate matching of anatomical (CT/MRI) and functional (PET) images. 3. Debate the strengths and limitations of emerging molecular imaging techniques compared to existing diagnostic tests. 4. Utilize performance characteristics of standard and emerging molecular imaging modalities to stage urologic oncology patients. 5. Describe the emerging role of PET imaging and novel radiotracers to assess chemotherapy and immunotherapy response.

Benjamin Pulli, MD, is a fellowship trained interventional neuroradiologist with a focus on vascular disorders of the brain, head/neck, and spine. He employs state-of-the-art minimally invasive endovascular and percutaneous surgical techniques to treat patients with intracranial aneurysms, acute stroke, brain arteriovenous malformations, dural arteriovenous fistulas, tumors, and chronic back pain. Having grown up in Austria, Dr. Pulli moved to the US after completing medical school in Innsbruck, Austria. He completed post-doctoral research training in Neuroradiology and Molecular Imaging at Harvard Medical School, followed by a Radiology residency and Neuroradiology fellowship training at the Massachusetts General Hospital in Boston. He then completed a second fellowship in Interventional Neuroradiology/Endovascular Neurosurgery at Stanford University. Dr. Pulli has authored more than 40 peer-reviewed publications and received prestigious scientific grants from institutions such as the Radiological Society of North America and Ernst Schering Foundation. To learn more about Dr. Pulli and other PNI Doctors please visit https://www.pacificneuroscienceinstitute.org/about-us/our-team/

On this episode, PrecisCa speaks with David M. Schuster MD, FACR. Dr. Schuster is a Professor in the Department of Radiology and Imaging Sciences at Emory University School of Medicine. Dr. Schuster also serves as Director of the Division of Nuclear Medicine and Molecular Imaging, and is a Georgia Research Alliance Distinguished Scientist. Board certified in radiology and nuclear medicine, he specializes in molecular medicine and integrative imaging. Dr. Schuster sits down with us to explain PET Scans, false readings & the importance of selecting the right scanners for the right situation. Visit www.precisca.com for more resources, content, and access to our entire catalogue of educational content. There you will have access to our complete library of educational videos. New episodes of the PrecisCa Oncology Podcast are released weekly. Please consider sharing our podcast, subscribing & turning on notifications to be the first to know about new releases. Together, we can raise the level of cancer care from diagnosis to recovery.

The key to being customer centric is understanding your customers. And the best way for you, as a marketer, to understand your customer is to leave the friendly confines of your office or Zoom call and actually engage with the people you're trying to market to. Sonia Sahney of GE Healthcare joins me for a discussion about customer insight, and ways to help your customers better understand their customers. Sonia is the CMO of Molecular Imaging at GE Healthcare. You can find her on LinkedIn.

In this week's episode, we talk to Dr. Jeff Thompson, Ph.D., NYPD detective and the creator of the Warr;or21 Project. This week's focus is on self-care and so much more.  We talk about the stresses that PIOs are faced with and how to manage themselves. Jeff explains how to normalize fear, stress, and anxiety. Jeff cover "reframing", which helps take control and gives perspective and the importance of it. Jeff explains what Warr;or21 Project is the Awe Project and the purpose of positivity for success. This episode is packed with great resources for anyone in a high-stress career. A bit about JeffJeff Thompson, Ph.D., is an Adjunct Associate Research Scientist at the Molecular Imaging and Neuropathology Research Area of the New York State Psychiatric Institute and also the Center for the Prevention and Treatment of Depression in the Psychiatry Department at Columbia University Medical Center.  His research includes developing resilience and positive mental health strategies, hostage negotiation in terrorist incidents, suicide prevention, psychological autopsies, and the use of effective communication during crisis incidents. His training material has been implemented in police agencies across the United States and beyond. Additionally, he is an 18-year law enforcement veteran detective with the New York City Police Department (NYPD) and a former hostage negotiator. In his role at the NYPD, Detective Thompson is currently the Mental Health and Wellness Coordinator helping conduct research and outreach on the department's suicide prevention and postvention efforts, reducing the stigma associated with mental illness and help-seeking, enhancing resilience through evidence-based practices, and raising awareness of resources available to both police officers and the public. Dr. Thompson is the recipient of the Griffith University Arts, Education and Law's 2020 Outstanding International Alumnus Award and The New York City Police Foundation's 2020 Hemmerdinger Award for Excellence for Distinguished Public Service.  Learn about Warr;or21 and the Awe Project by going to Resiliencesymposium.orgJeff's Twitter handle @jeffphd       Support the show (https://t.co/GOmAg9X6e8?amp=1)